Nipro Corp
Company Profile
Business description
Nipro Corp develops medical devices, most of which are related to dialysis and artificial organs. The firm is divided into three segment: Medical segment sells medical devices related to injections and infusions, artificial organs, high-performance devices, and dialysis, as well as pharmaceuticals related to diabetes, generics, and kit formulations in Japan and overseas; Pharmaceutical segment handles the consignment sales of pharmaceuticals from pharmaceutical companies, including containers for kit formulations; and Pharmaceutical Packaging handles glass for medical use in Japan, including glass for vials and ampoules, and glassware. Nipro generates the majority of its revenue in Japan, while it also has its presence in America, Europe and Asia.
Contact
3-26 Senrioka Shinmachi
Settsu City
Osaka566-8510
JPNT: +81 663106804
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
31 March 2027
Employees
39,763
Stocks News & Analysis
stocks
ASX major bank drives strong quarterly profit
stocks
Ask the analyst: What to expect in earnings season?
stocks
ASX healthcare share remains undervalued ahead of earnings
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,063.80 | 36.20 | 0.40% |
| CAC 40 | 8,406.06 | 33.78 | 0.40% |
| DAX 40 | 25,361.03 | 262.03 | 1.04% |
| Dow JONES (US) | 52,210.08 | 262.83 | 0.51% |
| FTSE 100 | 10,781.75 | 45.52 | 0.42% |
| HKSE | 25,207.18 | 243.95 | 0.98% |
| NASDAQ | 24,932.08 | 43.74 | -0.18% |
| Nikkei 225 | 64,931.19 | 320.04 | 0.50% |
| NZX 50 Index | 13,797.74 | 52.95 | -0.38% |
| S&P 500 | 7,413.18 | 1.20 | 0.02% |
| S&P/ASX 200 | 8,894.00 | 36.10 | 0.41% |
| SSE Composite Index | 3,858.25 | 44.05 | 1.15% |